SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The objective of this trial was to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female vaginal transmission of HIV infection among women at high risk. METHODOLOGY/PRINCIPAL FINDINGS: This was a Phase 3, double-blind, randomized, placebo-controlled trial. Participants made up to 12 monthly follow-up visits for HIV testing, adverse event reporting, and study product supply. The study was conducted between September 2004 and December 2006 in Lagos and Ibadan, Nigeria, where we enrolled 2153 HIV-negative women at high risk of HIV infection. Participants were randomized 1 ratio 1 to SAVVY or placebo. The effectiveness endpoint was incidence of HIV infection as indicated by detection of HIV antibodies in oral mucosal transudate (rapid test) or blood (ELISA), and confirmed by Western blot or PCR testing. We observed 33 seroconversions (21 in the SAVVY group, 12 in the placebo group). The Kaplan-Meier estimates of the cumulative probability of HIV infection at 12 months were 0.028 in the SAVVY group and 0.015 in the placebo group (2-sided p-value for the log-rank test of treatment effect 0.121). The point estimate of the hazard ratio was 1.7 for SAVVY versus placebo (95% confidence interval 0.9, 3.5). Because of lower-than-expected HIV incidence, we did not observe the required number of HIV infections (66) for adequate power to detect an effect of SAVVY. Follow-up frequencies of adverse events, reproductive tract adverse events, abnormal pelvic examination findings, chlamydial infections and vaginal infections were similar in the study arms. No serious adverse event was attributable to SAVVY use. CONCLUSIONS/SIGNIFICANCE: SAVVY did not reduce the incidence of HIV infection. Although the hazard ratio was higher in the SAVVY than the placebo group, we cannot conclude that there was a harmful treatment effect of SAVVY.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonspecific topical microbicides are ineffective for preventing HIV infection (40–45).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“We calculated Kaplan-Meier estimates [17] of HIV infection probabilities by treatment group, pooled across sites.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755 · cited 1×
“[1] We conducted this study under an IND to the U.”
MethodDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“[14–15] The analysis plan included a blinded assessment of whether additional participants would be needed to observe the required 66 events.”
MethodDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Tshibaka, L. M., Ettiègne-Traoré, V., Uaheowitchai, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11079-8 · Cited by 797 · cited 1×
“[6,7] C31G (SAVVYH) has a potent effect on enveloped HIV in vitro through a mechanism by which it disrupts the outer membrane.”
Kreiss, J. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490040053025 · Cited by 402 · cited 1×
“[6,7] C31G (SAVVYH) has a potent effect on enveloped HIV in vitro through a mechanism by which it disrupts the outer membrane.”
BackgroundRoddy, R. E., Zekeng, L., Ryan, K. A., Tamoufé, U., Weir, S. S., & Wong, E. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390803 · Cited by 366
Cited by
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
Skoler-Karpoff, S., Ramjee, G., Ahmed, K., Altini, L., Plagianos, M. G., Friedland, B., Govender, S., De Kock, A., Cassim, N., Palanee, T., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61842-5 · Cited by 502
McCormack, S., Ramjee, G., Kamali, A., Rees, H., Crook, A. M., Gafos, M., Jentsch, U., Pool, R., Chisembele, M., Kapiga, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61086-0 · Cited by 335
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic
Cohen, M. S., Hellmann, N., Levy, J. A., DeCock, K., & Lange, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34706 · Cited by 304
“However, multiple first-generation microbicides (nonoxynol-9, cellulose sulphate, and C31G [SAVVY]) have failed to protect in clinical trials (126–129).”
Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward
Padian, N. S., Buvé, A., Balkus, J., Serwadda, D., & Cates, W. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60885-5 · Cited by 264
Abdool Karim, S. S., Richardson, B. A., Ramjee, G., Hoffman, I. F., Chirenje, Z. M., Taha, T., Kapina, M., Maslankowski, L., Coletti, A., Profy, A., et al. (2011) · AIDS · doi:10.1097/qad.0b013e32834541d9 · Cited by 233
“The Savvy trial was halted early owing to futility.”
MethodWeighing the gold in the gold standard: challenges in HIV prevention research
Padian, N. S., McCoy, S. I., Balkus, J. E., & Wasserheit, J. N. (2010) · AIDS · doi:10.1097/qad.0b013e328337798a · Cited by 217
“Although the overall estimates for the cellulose sulfate [33] and SAVVY (C31G) gel [49] trials were nonsignificant, subgroup analyses revealed significant adverse results in the interim and per protocol analyses of the cellulose sulfate trial and among women in the SAVVY trial with greater than median coital frequency…”
ResultStructure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral Activity
Tyssen, D., Henderson, S. A., Johnson, A., Sterjovski, J., Moore, K., La, J., Zanin, M., Sonza, S., Karellas, P., Giannis, M. P., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012309 · Cited by 169
“Several candidate microbicides from the nonspecific and moderately specific classes have been evaluated in clinical trials and either demonstrate no efficacy or promote HIV acquisition in women [20,21,52,53].”
BackgroundVaginal microbicides and the prevention of HIV transmission
Cutler, B., & Justman, J. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70254-8 · Cited by 169
Halpern, V., Ogunsola, F., Obunge, O., Wang, C.-H., Onyejepu, N., Oduyebo, O., Taylor, D., McNeil, L., Mehta, N., Umo-Otong, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003784 · Cited by 155
Commensal Bacteria Modulate Innate Immune Responses of Vaginal Epithelial Cell Multilayer Cultures
Rose, W. A., McGowin, C. L., Spagnuolo, R. A., Eaves-Pyles, T. D., Popov, V. L., & Pyles, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032728 · Cited by 146
“Several promising topical agents designed to reduce or prevent experimental STI transmission have proven successful in clinical trials [18,19,20].”
BackgroundInácio, Â. S., Mesquita, K. A., Baptista, M., Ramalho-Santos, J., Vaz, W. L. C., & Vieira, O. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019850 · Cited by 141
Targeting Trojan Horse leukocytes for HIV prevention
Anderson, D. J., Politch, J. A., Nadolski, A. M., Blaskewicz, C. D., Pudney, J. A., & Mayer, K. H. (2009) · AIDS · doi:10.1097/qad.0b013e32833424c8 · Cited by 158
“Other compounds in this class, such as C31G, have not completed efficacy trials [276,277], but it is”
BackgroundDenton, P. W., Othieno, F. A., Martinez-Torres, F. J., Zou, W., Krisko, J. F., Fleming, E. H., Zein, S., Powell, D. A., Wahl, A. R., Kwak, Y. T., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00537-11 · Cited by 152
Kahle, E. M., Hughes, J. P., Lingappa, J. R., John-Stewart, G., Celum, C., Nakku-Joloba, E., Njuguna, S., Mugo, N., Bukusi, E., Manongi, R., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31827e622d · Cited by 132
Whither or Wither Microbicides?
Grant, R. M., Hamer, D. H., Hope, T. J., Johnston, R., Lange, J. M. A., Lederman, M. M., Lieberman, J., Miller, C. J., Moore, J. P., Mosier, D. E., et al. (2008) · Science · doi:10.1126/science.1160355 · Cited by 131
Karim, Q. A., Kharsany, A. B., Frohlich, J. A., Werner, L., Mashego, M., Mlotshwa, M., Madlala, B. T., Ntombela, F., & Abdool Karim, S. S. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyq176 · Cited by 121
Mesquita, P. M. M., Cheshenko, N., Wilson, S. S., Mhatre, M., Guzman, E., Fakioglu, E., Keller, M. J., & Herold, B. C. (2009) · The Journal of Infectious Diseases · doi:10.1086/600867 · Cited by 114
“Clinical trial failures with nonoxynol-9 (N-9), C31G (Savvy), Carraguard, and cellulose sulfate (CS) highlight the inadequacies of current assays [1-4].”
Polymeric gels for intravaginal drug delivery
Cook, M. T., & Brown, M. B. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.004 · Cited by 124
“Several factors may have contributed to the failure of the trial [139].”
BackgroundThurman, A. R., Clark, M. R., & Doncel, G. F. (2011) · Infectious Diseases in Obstetrics and Gynecology · doi:10.1155/2011/429403 · Cited by 95
Inácio, Â. S., Domingues, N. S., Nunes, A., Martins, P. A. T., Moreno, M. J., Estronca, L. M. B. B., Fernandes, R., Moreno, A. J., Borrego, M. J., Gomes, J. P., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv405 · Cited by 98
Inácio, Â. S., Costa, G. N., Domingues, N. S., Santos, M. S., Moreno, A. J., Vaz, W. L. C., & Vieira, O. V. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02437-12 · Cited by 110
“Regarding the use of surfactants for topical applications, epithelial cells are the first to come in contact with these molecules, and there is evidence that, at least in vaginal use, columnar epithelia are the most susceptible (26, 27).”
BackgroundChallenges of a Hidden Epidemic: HIV Prevention Among Women in the United States
Hodder, S., Justman, J. E., Haley, D. F., Adimora, A. A., Fogel, C. I., Golin, C. E., O’Leary, A., Soto-Torres, L. E., Wingood, G. M., & El‐Sadr, W. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181fbbdf9 · Cited by 99
Klimas, N. G., Koneru, A. O., & FLETCHER, M. A. (2008) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31817ae69f · Cited by 100
“This particular microbicide, SAVVY, did not reduce the incidence of HIV infection (41).”
BackgroundCarbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile
Chonco, L., Pion, M., Vacas‐Córdoba, E., Rasines, B., Maly, M., Serramía, M. J., López-Fernández, L. A., de la Mata, F. J., Álvarez, S., Gómez, R., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.050 · Cited by 89
Whaley, K. J., Hanes, J. S., Shattock, R. J., Cone, R. A., & Friend, D. R. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.09.006 · Cited by 88
“In one published microbicide trial (Feldblum et al., 2008), the percentage of sex acts in which the study gel was used and a condom was not was only 9%, severely limiting study power.”
BackgroundHigh Human Immunodeficiency Virus Incidence in a Cohort of Rwandan Female Sex Workers
Braunstein, S. L., Ingabire, C. M., Kestelyn, E., Uwizera, A. U., Mwamarangwe, L., Ntirushwa, J., Nash, D., Veldhuijzen, N. J., Nel, A., Vyankandondera, J., et al. (2011) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e31820b8eba · Cited by 83
Preventing mucosal HIV transmission with topical microbicides: Challenges and opportunities
Hladik, F., & Doncel, G. F. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.09.011 · Cited by 85
“…microbicides, such as surfactants and polyanions, have completed phase III clinical testing and none has demonstrated clear statistical evidence of protection (Feldblum et al., 2008; Halpern et al., 2008; Karim, 2010; Peterson et al., 2007; Van Damme et al., 2008; Van Damme et al., 2002).”
BackgroundMicrobicides for HIV prevention: reality or hope?
McGowan, I. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328334fe70 · Cited by 70
du Toit, L. C., Pillay, V., & Choonara, Y. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.022 · Cited by 81
Nunn, A., McCormack, S., Crook, A. M., Pool, R., Rutterford, C. M., & Hayes, R. (2009) · Trials · doi:10.1186/1745-6215-10-99 · Cited by 71
“More recent microbicide trial results, although disappointing, have not, like N9, demonstrated an obvious harmful microbicide effect [7-10].”
Efficacy dilution in randomized placebo-controlled vaginal microbicide trials
Mâsse, B. R., Boily, M., Dimitrov, D., & Desai, K. (2009) · Emerging Themes in Epidemiology · doi:10.1186/1742-7622-6-5 · Cited by 70
“For instance, the methycellulose gel used as the placebo in the Carraguard trial may have acted as a physical barrier and reduced HIV acquisition [12, 13 ].”
Chateau, M., Denton, P. W., Swanson, M. D., McGowan, I., & García, J. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060024 · Cited by 70
“Nevertheless, the vast majority of past and ongoing clinical trials for HIV prevention using topical microbicides have focused on preventing vaginal HIV-1 acquisition [5,9,20,29–36].”
BackgroundBunge, K. E., Dezzutti, C. S., Rohan, L. C., Hendrix, C. W., Marzinke, M. A., Richardson‐Harman, N., Moncla, B. J., Devlin, B., Meyn, L. A., Spiegel, H. M. L., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000897 · Cited by 72
Gali, Y., Delézay, O., Brouwers, J., Addad, N., Augustijns, P., Bourlet, T., Hamzeh‐Cognasse, H., Ariën, K. K., Pozzetto, B., & Vanham, G. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00456-10 · Cited by 67
“, cellulose sulfate, Savvy, Carraguard, and PRO-2000) showed no reduction or even an increased risk of acquiring HIV (10, 20, 29, 32).”
BackgroundPersisting with prevention: The importance of adherence for HIV prevention
Weiss, H. A., Wasserheit, J. N., Barnabas, R. V., Hayes, R., & Abu-Raddad, L. J. (2008) · Emerging Themes in Epidemiology · doi:10.1186/1742-7622-5-8 · Cited by 72
“[32-40] [41-43]”
Notario-Pérez, F., Ruíz, R., & Veiga, M.-D. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s133170 · Cited by 74
“20,21 23 This was not all; tests showed that not only is nonoxynol-9 ineffective in preventing HIV transmission, but also it increases the incidence of genital lesions such as vaginal ulcers, thus raising the risk of STIs.”
Microbicides and HIV prevention: lessons from the past, looking to the future
Morris, G. C., & Lacey, C. J. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328334de6d · Cited by 69
Keller, M. J., Mesquita, P. M. M., Torres, N. M., Cho, S., Shust, G. F., Madan, R. P., Cohen, H. W., Petrie, J., Ford, T., Soto-Torres, L. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008781 · Cited by 63
“Moreover, none of the previous microbicide clinical trials with other candidate drugs has demonstrated significant protection against HIV and in some trials, higher rates of infection were observed in the treatment compared to the placebo arm [3,4,5].”
ResultLu, L., Pan, C., Li, Y., Lü, H., He, W., & Jiang, S. (2012) · Retrovirology · doi:10.1186/1742-4690-9-104 · Cited by 62
“Krebs FC, Miller SR, Malamud D, Howett MK, Wigdahl B: Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate.”
BackgroundInfluentialSurfactants as microbicides and contraceptive agents: a systematic in vitro study
Vieira, O. V., Hartmann, D. O., Cardoso, C. M. P., Oberdoerfer, D., Baptista, M., Santos, M. A. S., Almeida, L., Ramalho-Santos, J., & Vaz, W. L. C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002913 · Cited by 61
“More recently Phase III studies have shown that C31G, a mixture of a zwitterionic and a nonionic surfactant, in a formulation known as ‘‘SAVVY Vaginal Gel’’ is also not useful in prevention of HIV infection in humans [8,9].”
BackgroundAntiviral mouthwashes: possible benefit for COVID-19 with evidence-based approach
Moosavi, M., Aminishakib, P., & Ansari, M. (2020) · Journal of Oral Microbiology · doi:10.1080/20002297.2020.1794363 · Cited by 70
“Its antiviral activity against enveloped viruses has been shown in previous studies [39,40].”
ResultThe Future of HIV Microbicides: Challenges and Opportunities
Garg, A. B., Nuttall, J. P., & Romano, J. (2009) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020901900401 · Cited by 59
“For example, gels have been used to formulate microbicides such as PRO2000 [46] and Savvy (a surface active compound that functions by disruption of the HIV envelope) [47]; both compounds have been evaluated in Phase IIb/III trials [48,49].”
MethodKramski, M., Wheatley, A. K., Jacobson, J. C., Alexander, M. R., Rawlin, G., & Purcell, D. F. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00453-12 · Cited by 62
“Despite the failure of previous microbicide trials (14, 51, 58, 59), the antiretroviral drug tenofovir demonstrated significant reduction in HIV acquisitions by 39% if used topically in a 1% gel (CAPRISA 004 trial) (24) but did not provide any protection if used orally (VOICE trial) (36).”
BackgroundAdherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection
Gengiah, T. N., Moosa, A., Naidoo, A., & Mansoor, L. E. (2013) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9861-1 · Cited by 61
“All trials testing SAVVY (C31G) were stopped prematurely for futility [22, 35] and all reported that considerable time off product due to high pregnancy rates and low retention which contributed to poor adherence.”
Ramjee, G., van der Straten, A., Chipato, T., de Bruyn, G., Blanchard, K., Shiboski, S., Cheng, H., Montgomery, E., Padian, N., & for the MIRA team (2008) · PLoS ONE · doi:10.1371/journal.pone.0003488 · Cited by 52
State of The Science of Adherence in Pre-Exposure Prophylaxis and Microbicide Trials
Muchomba, F. M., Gearing, R. E., Simoni, J. M., & El‐Bassel, N. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31826f9962 · Cited by 54
“At 12 months, 5 (26%) studies reported a retention rate of 70% or less.(23,24,28,31,39) On average, studies that reported recruiting sex workers had lower retention rates (73%) than those that did not (87%).”
BackgroundMensch, B., Hewett, P., Abbott, S. A., Rankin, J. C., Littlefield, S., Ahmed, K., Cassim, N., Patel, S., Ramjee, G., Palanee‐Phillips, T., et al. (2010) · AIDS and Behavior · doi:10.1007/s10461-010-9791-z · Cited by 53
Vaginal Mucosa and Drug Delivery
das Neves, J., Palmeira‐de‐Oliveira, R., Palmeira‐de‐Oliveira, A., Rodrigues, F., & Sarmento, B. F. C. C. (2014) · Wiley eBooks · doi:10.1002/9781118794203.ch05 · Cited by 64
The Importance of the Vaginal Delivery Route for Antiretrovirals in HIV Prevention
Ferguson, L. M., & Rohan, L. C. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.126 · Cited by 61
Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection
Marrazzo, J. M., & Cates, W. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir695 · Cited by 58
Moench, T. R., Mumper, R. J., Hoen, T. E., Sun, M., & Cone, R. A. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-331 · Cited by 51
“Importantly, the results in this and similar models [13] correlate well with trends toward or statistically significant adverse effects of microbicides on HIV endpoints in clinical studies [1-4].”
InfluentialBraunstein, S., van de Wijgert, J. H. H. M., & Nash, D. (2009) · PubMed · Cited by 60
Gali, Y., Ariën, K. K., Praet, M. M., den Bergh, R. V., Temmerman, M., Delézay, O., & Vanham, G. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.01.018 · Cited by 50
Assessment of topical microbicides to prevent HIV-1 transmission: Concepts, testing, lessons learned
Friend, D. R., & Kiser, P. F. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.06.021 · Cited by 53
Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers
Doncel, G. F., & Clark, M. R. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.09.018 · Cited by 48
HIV sexual transmission and microbicides
Ariën, K. K., Jespers, V., & Vanham, G. (2011) · Reviews in Medical Virology · doi:10.1002/rmv.684 · Cited by 58
“Analysis of 12 month follow up data in Nigeria from 2153 participants found an insignificant trend towards higher HIV incidence in the Savvy users compared to placebo [109].”
ResultObiero, J. A., Mwethera, P. G., Hussey, G. D., & Wiysonge, C. S. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-289 · Cited by 51
“The remaining studies had losses to follow-up ranging from 3% to 7% [20,22,25-27].”
BackgroundInfluentialVanić, Ž., Jøraholmen, M. W., & Škalko‐Basnet, N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113855 · Cited by 53
The last decade of microbicide clinical trials in Africa: from hypothesis to facts
Ramjee, G., Kamali, A., & McCormack, S. (2010) · AIDS · doi:10.1097/01.aids.0000390706.81383.f3 · Cited by 55
“FHI closes phase III trial of cellulose sulfate for HIV prevention; Research Triangle Park, NC: FHI, January 31, 2007. http://www.fhi.org/en/AboutFHI/ Media/Releases/res_CS_Nigeria.htm.”
BackgroundInfluentialNanotechnology and HIV: potential applications for treatment and prevention
Kim, P. S., & Read, S. W. (2010) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.118 · Cited by 45
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides
Adams, J. L., & Kashuba, A. D. M. (2012) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2012.01.004 · Cited by 53
Topical microbicides for prevention of sexually transmitted infections
Obiero, J. A., Mwethera, P. G., & Wiysonge, C. S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007961.pub2 · Cited by 54
Overview of microbicides for the prevention of human immunodeficiency virus
Karim, S. S. A., & Baxter, C. (2012) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2012.01.010 · Cited by 51
Women-specific routes of administration for drugs: A critical overview
das Neves, J., Notario-Pérez, F., & Sarmento, B. F. C. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113865 · Cited by 46
Herold, B. C., Mesquita, P. M. M., Madan, R. P., & Keller, M. J. (2010) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00932.x · Cited by 48
Recent advances on anti-HIV vaginal delivery systems development
Antimisiaris, S. G., & Mourtas, S. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.015 · Cited by 53
Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicide
Yamamoto, H. S., Xu, Q., & Fichorova, R. N. (2013) · BMC Microbiology · doi:10.1186/1471-2180-13-4 · Cited by 47
“A number of compounds with broad-spectrum anti-HIV activity in-vitro have successfully passed preclinical and Phase I evaluations, nevertheless, those selected for Phase II/III trials have failed to prevent HIV thus far [2-6].”
BackgroundKarim, Q. A., Kharsany, A. B., Frohlich, J. A., Baxter, C., Yende, N., Mansoor, L. E., Mlisana, K. P., Maarschalk, S., Arulappan, N., Grobler, A., et al. (2011) · Trials · doi:10.1186/1745-6215-12-67 · Cited by 37
“Topical microbicides offer an option for these women to reduce their HIV risk and to date several classes of products have undergone advanced clinical testing [15-20].”
BackgroundRamjee, G., Wand, H. C., Whitaker, C., McCormack, S., PADIAN, N. S., Kelly, C., & Nunn, A. (2011) · AIDS and Behavior · doi:10.1007/s10461-011-0043-7 · Cited by 40
Wall, K. M., Kilembe, W., Inambao, M., Chen, Y. N., Mchoongo, M., Kimaru, L. J., Hammond, Y. T., Sharkey, T., Malama, K., Fulton, T. R., et al. (2015) · Globalization and Health · doi:10.1186/s12992-015-0114-z · Cited by 42
“The latter issue is key for prevention or intervention trial preparedness: a recent systematic review observed HIV incidence was lower than expected in 73 % (8/11) of such trials [33], and two microbicide trials were halted due to low HIV incidence [34, 35].”
BackgroundPharmaceutical Vehicles for Vaginal and Rectal Administration of Anti-HIV Microbicide Nanosystems
Mesquita, L., Galante, J., Nunes, R., Sarmento, B. F. C. C., & das Neves, J. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030145 · Cited by 39
Burke, A. E., Barnhart, K. T., Jensen, J. T., Creinin, M. D., Walsh, T. L., Wan, L. S., Westhoff, C. L., Thomas, M. A., Archer, D. F., Wu, H., et al. (2010) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181fc3b1a · Cited by 40
Baseline Factors Associated With Incident HIV and STI in Four Microbicide Trials
Feldblum, P. J., Lie, C.-C., Weaver, M. A., Damme, L. V., Halpern, V., Adeiga, A., Bakare, R. A., Schwartz, J. L., Becker, M., & Solomon, S. (2010) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e3181e15f0b · Cited by 39
Self-citationMicrobicide delivery: formulation technologies and strategies
Romano, J., Malcolm, K. R., Garg, S., Rohan, L. C., & Kaptur, P. E. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328305b96e · Cited by 36
McGowan, I., & Taylor, D. J. (2010) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e3181cd70c2 · Cited by 34
Contraceptive Choices, Pregnancy Rates, and Outcomes in a Microbicide Trial
Sibeko, S., Baxter, C., Yende‐Zuma, N., Karim, Q. A., & Karim, S. S. A. (2011) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31822be512 · Cited by 35
Kaul, R., Rebbapragada, A., Hirbod, T., Wachihi, C., Ball, T. B., Plummer, F. A., Kimani, J., & Jaoko, W. G. (2008) · AIDS · doi:10.1097/qad.0b013e328311ac65 · Cited by 33
“Low rates of HIV acquisition after sexual exposure complicate the performance of HIV microbicide trials[8], and compounds with in vitro anti-HIV activity may actually increase HIV susceptibility[3].”
Microbicides in the Prevention of HIV Infection: Current Status and Future Directions
Nuttall, J. P. (2010) · Drugs · doi:10.2165/10898650-000000000-00000 · Cited by 34
Micsenyi, A., Zony, C., Alvarez, R. A., Durham, N. D., Chen, B. K., & Klotman, M. E. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit362 · Cited by 39
Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection
Ray, A., Ray, S., George, A. T., & Swaminathan, N. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008739.pub2 · Cited by 38
HIV-prevention science at a crossroads: advances in reducing sexual risk
Vermund, S. H., Allen, K. L., & Karim, Q. A. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32832c91dd · Cited by 33
Toward an information–motivation–behavioral skills model of microbicide adherence in clinical trials
Ferrer, R. A., Morrow, K. M., Fisher, W. A., & Fisher, J. D. (2010) · AIDS Care · doi:10.1080/09540121003623719 · Cited by 32
“Recent microbicide clinical trials report poor adherence, ranging from 44 to 78% consistency of use (El-Sadr et al. 2006; Feldblum et al., 2008; Littlefield et al., 2008; Peterson, Nanda, & Opoku, 2007).”
BackgroundMicrobicides: still a long road to success
Vanpouille, C., Arakelyan, A., & Margolis, L. B. (2012) · Trends in Microbiology · doi:10.1016/j.tim.2012.05.005 · Cited by 35
Adherence in the CAPRISA 004 Tenofovir Gel Microbicide Trial
Mansoor, L. E., Karim, Q. A., Yende‐Zuma, N., MacQueen, K. M., Baxter, C., Madlala, B. T., Grobler, A. C., & Karim, S. S. A. (2014) · AIDS and Behavior · doi:10.1007/s10461-014-0751-x · Cited by 36
“While findings from phase III trials of Nonoxynol-9 [2], SAVVY [3, 4], Carraguard [5] and Cellulose Sulphate [6, 7] have been disappointing, Tenofovir gel offers a promising female-controlled option as an effective microbicide for HIV prevention [8].”
Segarra, T. J., Fakioglu, E., Cheshenko, N., Wilson, S. S., Mesquita, P. M. M., Doncel, G. F., & Herold, B. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027675 · Cited by 32
“Particularly concerning were the observations that some products not only failed to protect against infection, but were associated with higher rates of HIV acquisition in placebo-controlled efficacy trials [2–4].”
BackgroundFriend, D. R. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1134485 · Cited by 28
“[48,49] Another class of compounds (polyanions) formulated as vaginal gels investigated for both contraceptive and”
BackgroundVaginal microbicides and their delivery platforms
D’Cruz, O. J., & Uckun, F. M. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.888055 · Cited by 32
“Early attempts to prevent the spread of sexual transmission of HIV with proven antiviral agents led to 10.1517/17425247.2014.888055 © 2014 Informa UK, Ltd. ISSN 1742-5247, e-ISSN 1744-7593 723 All rights reserved: reproduction in whole or in part not permitted the failure of 11 reported clinical trials with 6 non-spec…”
BackgroundInfluentialAbaasa, A. M., Asiki, G., Price, M. A., Ruzagira, E., Kibengo, F., Bahemuka, U. M., Fast, P., & Kamali, A. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.048 · Cited by 30
Advances in the Development of Microbicides for the Prevention of HIV Infection
Minces, L. R., & McGowan, I. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-009-0076-5 · Cited by 27
“, Baltimore, MD], and PRO-2000) without evidence of a reduction in HIV incidence [38–43].”
BackgroundNanotech-derived topical microbicides for HIV prevention: The road to clinical development
Sánchez-Rodríguez, J., Vacas‐Córdoba, E., Gómez, R., de la Mata, F. J., & Muñoz‐Fernández, M. Á. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.10.014 · Cited by 30
HIV pre-exposure prophylaxis trials: the road to success
Nicol, M. R., Adams, J. L., & Kashuba, A. D. M. (2013) · Clinical Investigation · doi:10.4155/cli.12.155 · Cited by 32
The clinical pharmacology of antiretrovirals for HIV prevention
Hendrix, C. W. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32835847ae · Cited by 26
Koblin, B. A., Andrasik, M. P., & Austin, J. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31829a3a4d · Cited by 29
“Preparedness studies do not guarantee ultimate trial participation(32) or accrual of samples with adequate HIV incidence rates.(33,34) Consequently, within a dynamic research environment, investigation into the shifting drivers of community engagement, enrollment, recruitment, and retention is needed, not only in prep…”
BackgroundPoynten, I. M., Millwood, I. Y., Falster, M. O., Law, M. G., Andresen, D. N., Damme, L. V., & Kaldor, J. M. (2009) · AIDS · doi:10.1097/qad.0b013e32832b4271 · Cited by 25
Mbopi‐Kéou, F., Trottier, S., Omar, R. F., Nkele, N. N., Fokoua, S., Mbu, E. R., Domingo, M.-C., Giguère, J.-F., Piret, J., Mwatha, A., et al. (2009) · Contraception · doi:10.1016/j.contraception.2009.07.002 · Cited by 27
“002 microbicides are potentially powerful tools in HIV prevention, their development has been hampered by candidate products showing lack of protection against HIV/AIDS in Phase III clinical trials [2–4].”
BackgroundCost, M. R., Dezzutti, C. S., Clark, M. R., Friend, D. R., Akil, A., & Rohan, L. C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06284-11 · Cited by 24
“Until recently, several microbicide products evaluated in clinical trials failed to show protection against HIV-1 transmission (2, 15, 20, 34, 35).”
BackgroundProtein/peptide‐based entry/fusion inhibitors as anti‐HIV therapies: challenges and future direction
Fumakia, M., Yang, S., Gu, J., & Ho, E. A. (2015) · Reviews in Medical Virology · doi:10.1002/rmv.1853 · Cited by 26
Rudy, B. J., Kapogiannis, B. G., Lally, M., Gray, G., Bekker, L., Krogstad, P. A., & McGowan, I. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181e3a922 · Cited by 27
Metadata
- Authors
- Feldblum, P. J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., Olayemi, M. O., Wang, L., Nanda, K., & Rountree, W.
- Affiliations
- Family Health International 360 (US)
- Nigerian Institute of Medical Research (NG)
- University of Ibadan (NG)
- Corresponding author
- Feldblum, Paul J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-01-23
- Volume
- 3
- Issue
- 1
- Pages
- e1474
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2190795
- OpenAlex
- W2160780945
- Cited by
- 280
- References
- 28
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 5 · 2018: 2 · 2017: 5 · 2016: 6 · 2015: 14 · 2014: 22 · 2013: 27 · 2012: 42
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- United States Agency for International Development (GPO-A-00-05-00022-00)
- U.S. Food and Drug Administration
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- HIV prevention, vaginal microbicides, HIV seroconversion, HIV incidence, adverse events, chlamydia, vaginal infection
- MeSH terms
- Double-Blind Method, Female, Gels, Humans, Male, Nigeria, Patient Compliance, Placebos, Sexual Behavior, Vagina, HIV Infections, Anti-HIV Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
